235

Ўткир респиратор синдромли коронавирус Corona Virus Disease 2019 пандемияси глобал соғлиқни сақлаш тизимига жиддий хавф туғдирмоқда. Ҳозирда биз бутун дунё бўйлаб клиник тадқиқотлар сонининг ортиб бораётганига гувоҳ бўлмоқдамиз. Клиник тадқиқотларда дорилар, шу жумладан, замонавий ва олдинги замон дори воситаларининг потенциал даволаш усуллари сифатида ёки уларнинг вирусга қарши фаоллиги ҳамда Corona Virus Disease 2019 инфекциясига хос бўлган нафас ва юрак-қон томир белгилари ва асоратларига таъсир қилиш қобилияти клиник тадқиқот синовларидан ўтмоқда. Corona Virus Disease 2019 инфекциясининг ёмон тенденциясига қарамай, кенг кўламли тадқиқотларда бирон-бир дори воситасининг Corona Virus Disease 2019 билан оғриган беморларни клиник даволашда сезиларли даражада самарадор эканлиги исботланмаган. Бундай стратегия терапияни персонификация қилиш учун хавф гуруҳларини аниқлашда дастлабки фармакогенетик тадқиқотлар ёрдамида ечилиши мумкин бўлган хавфсизлик ва самарадорлик борасида бир қатор муаммоларга олиб келиши мумкин. Corona Virus Disease 2019 инфекцияси тиббий даволашнинг персонификация масаласини ҳал қилиш клиник тадқиқотларнинг қарама-қарши натижаларини талқин қилиш ва маълум бир дори воситасининг аниқ самарадорлигини аниқлаш учун зарурий эҳтиёжга айланади

  • Web Address
  • DOIhttps://dx.doi.org/10.36522/2181-9637-2020-4-12
  • Date of creation in the UzSCI system 07-04-2022
  • Read count 235
  • Date of publication 10-09-2020
  • Main LanguageO'zbek
  • Pages123-133
Ўзбек

Ўткир респиратор синдромли коронавирус Corona Virus Disease 2019 пандемияси глобал соғлиқни сақлаш тизимига жиддий хавф туғдирмоқда. Ҳозирда биз бутун дунё бўйлаб клиник тадқиқотлар сонининг ортиб бораётганига гувоҳ бўлмоқдамиз. Клиник тадқиқотларда дорилар, шу жумладан, замонавий ва олдинги замон дори воситаларининг потенциал даволаш усуллари сифатида ёки уларнинг вирусга қарши фаоллиги ҳамда Corona Virus Disease 2019 инфекциясига хос бўлган нафас ва юрак-қон томир белгилари ва асоратларига таъсир қилиш қобилияти клиник тадқиқот синовларидан ўтмоқда. Corona Virus Disease 2019 инфекциясининг ёмон тенденциясига қарамай, кенг кўламли тадқиқотларда бирон-бир дори воситасининг Corona Virus Disease 2019 билан оғриган беморларни клиник даволашда сезиларли даражада самарадор эканлиги исботланмаган. Бундай стратегия терапияни персонификация қилиш учун хавф гуруҳларини аниқлашда дастлабки фармакогенетик тадқиқотлар ёрдамида ечилиши мумкин бўлган хавфсизлик ва самарадорлик борасида бир қатор муаммоларга олиб келиши мумкин. Corona Virus Disease 2019 инфекцияси тиббий даволашнинг персонификация масаласини ҳал қилиш клиник тадқиқотларнинг қарама-қарши натижаларини талқин қилиш ва маълум бир дори воситасининг аниқ самарадорлигини аниқлаш учун зарурий эҳтиёжга айланади

Русский

Пандемия Corona Virus Disease 2019, вызванная SARS-CoV-2 – коронавирусом тяжелого острого респираторного синдрома, представляет собой серьезную глобальную угрозу для мирового здравоохранения. Во всем мире проводятся клинические исследования старых и новых препаратов в качестве потенциальных методов лечения по их прямой антивирусной активности или способности обеспечить воздействие на респираторные, сердечно-сосудистые симптомы и другие осложнения, характерные для коронавирусной инфекции. Проведенными исследованиями до сих пор не доказана значительная эффективность ни одного лекарственного препарата при клиническом лечении больных Corona Virus Disease 2019. Такая стратегия может привести к ряду проблем безопасности и эффективности, которые могут быть решены с помощью подхода предварительного проведения фармакогенетических исследований по выделению групп риска для персонификации терапии. Решение задачи персонификации медикаментозного лечения Corona Virus Disease 2019 становится настоятельной необходимостью в интерпретации полученных противоречивых результатов клинических испытаний и установления явной эффективности какого-либо конкретного препарата

English

The pandemic of Corona Virus Disease 2019 infection, caused by severe acute respiratory syndrome coronavirus, has posed a significant threat to global health. We are now witnessing an unsurpassed increase in the number of clinical trials worldwide. Old and new drugs are tested in clinical trials as potential treatments either for their direct anti-viral activity or for their ability to induce effects on respiratory and cardiovascular symptoms and complications specific to Corona Virus. Despite the law trends of Corona Virus, large-scale studies have not proven significant effectiveness in the clinical treatment of patients with coronavirus 2019. Such a strategy is likely to give rise to a range of safety and efficacy challenges that could be addressed through preliminary pharmaco-genetic studies to identify the risk groups for personification of therapy approach. Addressing the personification of drug treatment Corona Virus Disease 2019 becomes an urgent need to interpret the conflicting results of clinical trials and establish the apparent efficacy of any particular drug.

№ Author name position Name of organisation
1 Mavlyanov I.R. tibbiyot fanlari doktori, professor, “Klinik farmakologiya” kafedrasi mudiri Toshkent vrachlar malakasini oshirish instituti
2 Mavlyanov Z.I. tibbiyot fanlari doktori, “Klinik farmakologiya” kafedrasi dotsenti Toshkent vrachlar malakasini oshirish instituti
3 Ashirmetov A.X. tibbiyot fanlari doktori, katta ilmiy xodim, yetakchi mutaxassis O'zbekiston Respublikasi Sog'liqni saqlash vazirligi
№ Name of reference
1 McCloskey B., Heymann D.L. SARS to novel coronavirus: old lessons and new lessons // Epidemiol. Infect. – 2020. – 22:e22.
2 Majumder M.S., Mandl K.D. Early in the epidemic: impact of preprints on global discourse about COVID-19 transmissibility // Lancet Glob Health. – 2020. – March 24. – Аccess mode: https://doi.org/10.1016/S2214-109X(20)30113-3.
3 Liu W., Morse J.S., Lalonde T. et al. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV // Chembiochem. – 2020. –N 21 (5). – Pp. 730-738.
4 Hoffmann M., Kleine-Weber H., Krüger N. et al. The novel coronavirus 2019 (2019- nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells // BIOR. – XIV. – 2020. – Pp. 2022-2023.
5 Li T., Lu H., Zhang W. Clinical observation and management of COVID-19 patients // Emerg Microbes Infect. – 2020. – N 9 (1). – Pp. 687-690.
6 Varga Z., Flammer A.J., Steiger P. et al. Endothelial cell infection and endotheliitis in COVID-19 // Lancet. – 2020. – S0140–736(20)30937–5.
7 Dalamaga M., Karampela I., Mantzoros C.S. 19 treatment regimens? // Metabolism. – 2020. – May 8. – Аccess mode: https://doi.org/10.1016/j.metabol.2020.154260/.
8 Rivellese F. ACE2 at the centre of COVID-19 from paucisymptomatic infections to severe pneumonia / F. Rivellese, Е. Prediletto, W. Harvey, Q. Mary // Autoimmunity Reviews. – 2020. – N 19. – 102536. – Аccess mode: https://doi.org/10.1016/j.autrev.2020. 102536/.
9 Qin C., Zhou L., Hu Z. et al. Dysregulation of immune response in patients with COVID19 in Wuhan // China Clin Infect Dis. – 2020. – Аccess mode: https://doi.org/10.1093/ cid/ciaa248/.
10 Li G., Fan Y., Lai Y. et al. Coronavirus infections and immune responses // J Med Virol. – 2020. – N 92. – Pp. 424-432.
11 Prompetchara E., Ketloy C., Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic // Asian Pac J Allergy Immunol. – 2020. – N 38. – Pp. 1-9.
12 Totura A.L., Baric R.S. SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon // Curr Opin Virol. – 2012. –N 2. – Pp. 264-275.
13 Pedersen F., Ho Y.C. SARS-CoV-2: a storm is raging //J. Clin. Invest. – 2020. – Аccess mode: https://doi.org/10.1172/JCI137647/.
14 Harapan H., Itoh N., Yufika A. et al. Coronavirus disease 2019 (COVID-19): A literature review // Journal of Infection and Public Health. – 2020. – N 13. – Pp. 667-673.
15 Liu W., Li H. COVID-19: Attacks the 1-Beta chain of hemoglobin and captures the Porphyrin to inhibit human Heme metabolism. – 2020. – Аccess mode: https://doi.org/- 10.26434/chemrxiv.11938173.v7/.
16 Drakesmith H., Prentice A. Viral infection and iron metabolism // Nat Rev Microbiol. – 2008. – N 6. – Pp. 541-552.
17 Wessling-Resnick M. Iron homeostasis and the inflammatory response // Annu Rev Nutr. – 2010. – N 30. –Pp. 105-122.
18 Ali M.K., Kim R.Y., Brown A.C. et al. Critical role for iron accumulation in the pathogenesis of fibrotic lung disease // J Pathol. – 2020. – Feb 21. – Аccess mode: https://doi.org/10.1002/path.5401/
19 Favallia E.G., Ingegnolia F., De Lucia O. et al. COVID-19 infection and rheumatoid arthritis: Faraway, so close! // Autoimmunity Reviews. –2020. – N 19. – Аccess mode: https://doi.org/10.1016/ j.autrev.2020.102523/.
20 Caso F., Costa L., Ruscitti P. et al. Could Sarscoronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? // Autoimmun Rev. – 2020. – Аccess mode: https://doi.org/10.1016/j.autrev.2020.102524/.
21 Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. // Lancet. – 2020. – Аccess mode: https://doi.org/10.1016/S0140-6736(20)30566-3/.
22 Caso F., Costa L., Ruscitti P. et al. Could Sarscoronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? // Autoimmun Rev. – 2020. – Аccess mode: https://doi.org/10.1016/j.autrev.2020.102524/.
23 Cao B., Wang Y., Wen D. et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19 // N Engl J Med. – 2020. – Mar 18. – Аccess mode: https://doi.org/ 10.1056/NEJMoa 2001282/.
24 Yu-chen Cao, Qi-xin Deng, Shi-xue Dai. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence // Travel Medicine and Infectious Disease [Published Online]. – 2020. – Аccess mode: https://www.elsevier.com/ locate/tmaid/1-s2.0-S1477893920301162/
25 Chong C.R., Sullivan D.J.Jr. New uses for old drugs // Nature. – 2007. – N 448 (7154). – Pp. 645-646.
26 Smith N., Fraser M. Straining the System: Novel Coronavirus (COVID-19) and Preparedness for Concomitant Disasters // Am J Public Health. – 2020. – N 110 (5). – P. 649.
27 Zhang H., Saravanan K.M., Yang Y. et al. Deep Learning Based Drug Screening for Novel Coronavirus 2019-nCoV // Preprints. – 2020. – Аccess mode: https://www.preprints.org /manuscript /202002.0061/v1/. – DOI: 10.20944/ preprints202002.0061.v1/
28 Lim J., Jeon S., Shin H.Y. et al. Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR // J Korean Med Sci. – 2020. – N 35 (6).
29 Lythgoe M.P., Middleton P. Ongoing Clinical Trials for the Management of the COVID19 Pandemic // Trends in Pharmacological Sciences. – 2020. – Аccess mode: https://doi.org/ 10.1016/j.tips.2020.03.006/.
30 Li H., Wang Y.M., Xu J.Y. et al. Potential antiviral therapeutics for 2019 Novel Coronavirus // Zhonghua Jie He Hu Xi Za Zhi. – 2020. – N 43 (3). – Pp. 170-172.
31 Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV) // Biosci Trends. – 2020. – N 14 (1). – Pp. 69-71.
32 Wen Zhanga, Yan Zhaoa, Fengchun Zhanga et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China // Clinical Immunology. – 2020. – Аccess mode: https://doi.org/10.1016/j.clim.2020. 108393/.
33 Suba Z. Prevention and Therapy of COVID-19 via Exogenous Estrogen Treatment for Both Male and Female Patients: An Opinion Paper // J Pharm Pharm Sci. – 2020. – N 23. – Pp. 75-85.
34 Rui Zhanga, Xuebin Wanga, Leng Nia et al. COVID-19: Melatonin as a potential adjuvant treatment // Life Sciences. – 2020. – Аccess mode: https://doi.org/10.1016/j. lfs.2020.117583/.
35 Carbonib E., Cartaa A.R., Carbonia E. Can pioglitazone be potentially useful therapeutically in treating patients with covid-19? // Medical Hypotheses. – 2020. – Аccess mode: https://doi.org/10.1016/j.mehy.2020.109776/.
36 Cure E., Cure M.C. Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis Diabetes & Metabolic Syndrome // Clinical Research & Reviews. – 2020. – N 14. – Pp. 405-406.
37 Zumla A., Chan J.F.W., Azhar E.I. et al. Coronaviruses – drug discovery and therapeutic options // Drug discovery. – 2016. –N 15. – Pp. 327-346.
38 Abreu G.E.A. Amantadine as a drug to mitigate the effects of COVID-19 / G.E.A. Abreu, M.E.H. Aguilar, D.H. Covarrubias, F.R. Durán // Medical Hypotheses. – 2020. – Аccess mode: https://doi.org/10.1016/j.mehy.2020.109755/.
39 Farouka A., Salmanb S. Dapsone and doxycycline could be potential treatment modalities for COVID-19 // Medical Hypotheses. – 2020. – Аccess mode: https://doi.org/ 10.1016/j.mehy.2020.109768/.
40 Sheahan T.P., Sims A.C., Leist S.R. et al. Comparative therapeutic efficacy of Remdesivir and combination Lopinavir, ritonavir, and interferon beta against MERS–COV // Nat Commun. – 2020. – N 11. – P. 222.
41 Meynard J.L., Moinot L., Landman R. et al. Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM) // J Antimicrob Chemother. – 2018. – N 73. – Pp. 1672–1676. – Аccess mode: https://doi.org/10.1093/jac/dky055/
42 Sham H.L. et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease // Antimicrob. Agents Chemother. – 1998. – N 42. – Pp. 3218-3224.
43 Van der Laan L.E., Garcia-Prats A.J., Schaaf H.S. et al. Pharmacokinetics and drug– drug interactions of lopinavir–ritonavir administered with first- and second-line antituberculosis drugs in HIV-infected children treated for multidrug-resistant tuberculosis // Antimicrob Agents Chemother. – 2018. – N 62. – pii: e00420-17. – Аccess mode: https://doi.org/10.1128/aac.00420-17/
44 Mallal S., Nolan D., Witt C. et al. Association between presence of HLA-B*5701, HLADR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir // Lancet. – 2002. – N 359. – Pp. 727-732.
45 Littera R., Carcassi C., Masala A. et al. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients // AIDS. – 2006. – N 20. – Pp. 1621-1626.
46 Rotger M., Colombo S., Furrer H. et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients // Pharmacogenet Genom. – 2005. – N 15. – Pp. 1-5
47 Dickinson L., Chaponda M., Carr D.F. et al. Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi // Antimicrobial Agents Chemother. – 2014. – N 58. – Pp. 706-712.
48 Martín A.S., Gómez A.I., García-Berrocal B. et al. Dose reduction of efavirenz: an observational study describing cost-effectiveness, pharmacokinetics and pharmacogenetics // Pharmacogenomics. – 2014. – N 15. – Pp. 997-1006.
49 Pavlos R., Phillips E.J. Individualization of antiretroviral therapy // Pharmgenomics Pers Med. – 2012. – N 5. – Pp. 1-17.
50 Anderson P.L., Lamba J., Aquilante C.L. et al. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study // J Acquir Immune Defic Syndr. – 2006. – N 42. – Pp. 441-449.
51 Мавлянов И.Р. Лекарственная аллергия: иммуннофармакологические аспекты / И.Р. Мавлянов, А.Х. Аширметов, З.И. Мавлянов, Н.В. Пирматова. – Т., 2015. – 102 с.
52 Мавлянов И.Р. Персонализированная фармакотерапия: цитохром Р-450 и его изoформы / И.Р. Мавлянов, А.Х. Аширметов, А.Ш. Касимов, З.И. Мавлянов. – Т., 2016. – 300 с.
53 Mavlyanov I.R. Cytochrome P-450: genetic and population aspects / I.R. Mavlyanov, A.Kh. Ashirmetov, Z.I. Mavlyanov, G.I. Jarilkasinova. – Kosice, 2017. – 224 p.
Waiting